Inclisiran for High Cholesterol (ORION-13 Trial)

"The target patients for this study are those who suffer from hyperlipoproteinemia type ii and are between the ages of 12 to 17. So far, the study has recruited 12 individuals."

"Inclisiran is used to lower cholesterol levels in patients with primary hypercholesterolemia. Additionally, this medication can be employed to prevent atherosclerotic cardiovascular disease in those struggling with conditions like diet-induced hypercholesterolemia."

"Inclisiran's journey from initial research to Phase 3 approval spanned 2018. The first clinical trial, sponsored by Novartis Pharmaceuticals, involved 15000 patients. Post-trial, Inclisiran was approved for Phase 3 drug trials. Currently, there are 11 ongoing trials in 588 different cities and 52 countries worldwide."

"That is correct. Our research shows that this study, which was first advertised on February 16th 2021, is still looking for participants. They need 12 people in total and have 4 different sites where the trial is taking place."

"Inclisiran has received a 3 on our safety scale at Power. This is because it is currently in Phase 3 clinical trials, which suggests that while there is some data affirming its efficacy, there are multiple rounds of data supporting its safety."

"There are currently 11 clinical trials underway for Inclisiran. 10 of those studies are in the final Phase 3 stage. Most of the research locations for Inclisiran are based in Ciudad de Mexico, but there are a total of 1414 sites running trials for this treatment worldwide."

"Yes, this information is available on clinicaltrials.gov. The trial was posted on February 16th, 2021 and has been actively recruiting since then with the most recent edit being made on July 29th, 2022."

"The age limit for this particular clinical trial is 12-17. Out of the 81 total trials, 14 are geared towards children and 67 are for adults over the age of 65."